PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Trial Information

PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

PNT2258 will be administered at a dose of 120 mg/m2, as a 3-hour intravenous (IV) infusion
on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression
or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.

a. A positive scan is defined per revised Cheson criteria as "focal or diffuse FDG
uptake above background in a location incompatible with normal anatomy or physiology,
without a specific standardized uptake value cutoff".

6. Disease that has relapsed after administration of primary therapy that included:

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.